Correlation Between Tel Aviv and Lineage Cell

Can any of the company-specific risk be diversified away by investing in both Tel Aviv and Lineage Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tel Aviv and Lineage Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Tel Aviv 35 and Lineage Cell Therapeutics, you can compare the effects of market volatilities on Tel Aviv and Lineage Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tel Aviv with a short position of Lineage Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tel Aviv and Lineage Cell.

Diversification Opportunities for Tel Aviv and Lineage Cell

-0.65

Correlation Coefficient

Tel Aviv  Lineage Cell

Excellent diversification

The 3 months correlation between Tel and Lineage is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding Tel Aviv 35 and Lineage Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lineage Cell Therapeutics and Tel Aviv is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tel Aviv 35 are associated (or correlated) with Lineage Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lineage Cell Therapeutics has no effect on the direction of Tel Aviv i.e., Tel Aviv and Lineage Cell go up and down completely randomly.

Pair Corralation between Tel Aviv and Lineage Cell

Assuming the 90 days trading horizon Tel Aviv 35 is expected to generate 0.19 times more return on investment than Lineage Cell. However, Tel Aviv 35 is 5.15 times less risky than Lineage Cell. It trades about 0.15 of its potential returns per unit of risk. Lineage Cell Therapeutics is currently generating about -0.02 per unit of risk. If you would invest  173,548  in Tel Aviv 35 on September 14, 2024 and sell it today you would earn a total of  59,998  from holding Tel Aviv 35 or generate 34.57% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	99.52%
Values	Daily Returns

Tel Aviv 35  vs.  Lineage Cell Therapeutics

Pair Trading with Tel Aviv and Lineage Cell

The main advantage of trading using opposite Tel Aviv and Lineage Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tel Aviv position performs unexpectedly, Lineage Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lineage Cell will offset losses from the drop in Lineage Cell's long position.

The idea behind Tel Aviv 35 and Lineage Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.